NEW YORK, March 16, 2015 /PRNewswire/ — Securities lawyers atDunnam & Dunnam are investigating allegations for Conatus Pharmaceuticals Inc. shareholders (CNAT). Concerned CNAT investors who purchased between July 25, 2013 and March 5, 2015 are encouraged to contact securities attorney Hamilton Lindley by clicking here.
The law firm’s investigation will focus on potential violations of the federal securities laws by Conatus Pharmaceuticals Inc. After close of trading on March 5, 2015, Conatus announced that Gary Burgess tendered his resignation as Senior Vice President of Clinical Research and Chief Medical Officer effective April 2, 2015. Shares of Conatus fell $0.54 per share to $6.05 on this news, or more than 8.1%, on March 6, 2015. Our potential shareholder lawsuit will seek to ensure that Conatus Pharmaceuticals Inc. works to enrich shareholders, not just the management.
Dunnam & Dunnam has significant experience representing shareholders in securities lawsuits nationwide. CNAT stockholders – or anyone with knowledge about this situation – should contact lawyer Hamilton Lindley at firstname.lastname@example.org with questions, toll free at (844) 702-2990 or visit http://www.dunnamlaw.com/CNAT.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/conatus-pharmaceuticals-inc-investors-encouraged-to-contact-securities-law-firm-about-investigation-into-allegations-of-corporate-wrongdoing-300050482.html